Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals (Q40353315)

19 September 2017

Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals (English)

1 reference

19 September 2017

0 references

1 reference

Mincheff M

1

1 reference

19 September 2017

Zoubak S

series ordinal

2

1 reference

19 September 2017

Makogonenko Y

series ordinal

3

1 reference

19 September 2017

1 April 2006

1 reference

19 September 2017

1 reference

19 September 2017

13

1 reference

19 September 2017

436-444

1 reference

19 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700914

19 September 2017

0 references

cites work

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Cloning and characterization of a novel peptidase from rat and human ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

DNA vaccines: an active immunization strategy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

The role of CpG dinucleotides in DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Mechanisms and therapeutic applications of immune stimulatory cpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Cytokines and costimulatory molecules as genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Prostate-specific membrane antigen in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

The JAM test. A simple assay for DNA fragmentation and cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

Vaccine adjuvancy: a new potential area of development for GM-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

CpG motifs as immune adjuvants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700914

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700914

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference